Drug delivery to the small airways

American Journal of Respiratory and Critical Care Medicine

Volumn 157, Issue 5 II SUPPL., 1998, Pages

  Thompson, Philip J ^a  

^a PATHWEST LABORATORY MEDICINE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

TERBUTALINE;

AEROSOL; BRONCHIOLE; DRUG DELIVERY SYSTEM; FORCED EXPIRATORY VOLUME; MEDICAL NEBULIZER; PARTICLE SIZE; PRIORITY JOURNAL; RESPIRATORY SYSTEM; REVIEW;

EID: 0031749352     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/ajrccm.157.5.rsaa-7     Document Type: Review

References (31)

1. Newhouse, M. T. 1990. Managing reversible airflow obstruction: role of MDI accessory devices, powder inhalers and nebulisers. Respirology June:1-15.
2. Lipworth, B. J. 1995. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 50:105-110.
3. Ariyananda, P. L., S. W. Clarke, and J. E. Agnew. 1996. Aerosol delivery systems for bronchial asthma. Postgrad. Med. J. 72:151-156.
4. Mortonen, T., and Y. Yang. 1996. Deposition mechanics of pharmaceutical particles in human airways. In A. J. Hickey, editor. Inhalational Aerosols: Physical and Biological Basis for Therapy. Marcel Dekker, New York. 1-21.
5. Vincent, J. H. 1985. On the practical significance of electrostatic lung deposition of isometric fibrous aerosols. J. Aerosol Med. 16:511-519.
6. Ferron, G. A. 1994. Aerosol properties and lung deposition. Eur. Respir. J. 7:1392-1394.
7. Martonen, T. B. 1992. The behavior of cigarette smoke in human airways. Am. Ind. Hyg. Assoc. J. 53:6-15.
8. Rudolph, G., R. Kobrich, and W. Stahlhofen. 1990. Modelling and algebraic formulation of regional aerosol deposition in man. J. Aerosol. Med. 21(Suppl. 1):S306-S406.
9. James, A. C., G. Rudolf, and W. Stahlhofen. 1991. The respiratory tract deposition model proposed by the ICRP task group. Rad. Prot. Dos. 38:159-165.
10. Clark, A. R. 1995. The use of laser defraction for the evaluation of the aerosol clouds generated by medical nebulisers. Int. J. Pharm. 115:69-78.
11. Newman, S. P. 1984. Production of radioaerosols. In S. W. Clarke and D. Pavia, editors. Aerosols and the Lung. Butterworth and Co., London. 71-89.
12. Cheah, P. K. P., and C. N. Davies. 1984. The spinning top aerosol generator-improving the performance. J. Aerosol Med. 15:741-751.
13. Newman, S. P. 1993. Scintigraphic assessment of therapeutic aerosols. Crit. Rev. Ther. Drug Carrier Syst. 10:65-109.
14. Borgstrom, L., and M. Nilsson. 1990. A method for determination of the absolute pulmonary bioavailability of inhaled drugs: terbutaline. Pharm. Res. 7:1068-1070.
15. 99mTc labelled particles for aerosol studies. Radiochem. Radioanal. Lett. 5:275-277.
16. Melchor, R., M. F. Biddiscombe, V. H. F. Mak, M. D. Short, and S. G. Spiro. 1993. Lung deposition patterns of directly labelled salbutamol in normal subjects and in patients with reversible airflow obstruction. Thorax 48:506-511.
17. Thorsson, L., S. Edsbacker, and T. B. Conradsson. 1994. Lung deposition of budesonide from Turbuhaler is twice that from a pressurised metered dose inhaler. Eur. Respir. J. 7:1839-1844.
18. Zainudin, B. N. Z., M. Biddiscombe, S. E. J. Tolfree, M. Short, and S. G. Spiro. 1993. Comparison of bronchodilator response and deposition patterns of salbutamol inhaled from a pressurised aerosol metered dose inhaler, as a dry powder and as a nebulised solution. Thorax 45:469-473.
19. Short, M. D., C. A. Singh, J. D. Few, P. R. Studdy, P. J. D. Heaf, and S. G. Spiro. 1981. The labelling and monitoring of lung deposition of an inhaled synthetic anticholinergic bronchodilating agent. Chest 80(Suppl.):918S-921S.
20. Newman, S. P., A. W. B. Weisz, N. Talaee, and S. W. Clark. 1991. Improvement of drug delivery with a breath actuated pressurised aerosol for patients with poor inhaler technique. Thorax 46:712-716.
21. Zanen, P., T. L. Go, and J. W. J. Lammers. 1996. Optimal particle size for beta 2 agonist and anticholinergic aerosols in patients with severe airflow obstruction. Thorax 51:977-980.
22. Zanen, P., T. L. Go, and J. W. J. Lammers. 1995. The optimal particle size for parasymathicolytic aerosols in mild asthmatics. Int. J. Pharm. 114:111-115.
23. Zanen, P., T. L. Go, and J. W. J. Lammers. 1994. The optimal particle size for Beta adrenergic aerosols in mild asthmatics. Int. J. Pharm. 107:211-217.
24. Mitchell, D. M., M. A. Solomon, S. E. J. Tolfree, M. Short, and S. G. Spiro. 1993. The effect of particle size of bronchodilator aerosols on lung function-in patients with chronic asthma. Thorax 48:506-511.
25. Clay, M. M., D. Pavia, and S. W. Clarke. 1986. Effect of aerosol particle size on bronchodilatation with nebulised terbutaline in asthmatic subjects. Thorax 41:364-368.
26. Johnson, M. A., S. P. Newman, and R. Bloom. 1989. Delivery of albuterol and ipratropium bromide from two nebulizer systems in chronic stable asthma: efficacy and pulmonary deposition. Chest 96:6-10.
27. Selroos, O., A. Pietinalho, and H. Riska. 1986. Delivery devices for inhaled asthma medication - clinical implications of differences in effectiveness. Clin. Immunotherapy 6:273-299.
28. Borgstrom, O., and S. P. Newman. 1993. Total and regional lung deposition of terbutaline sulphate inhaled via a pressurised MDI or via a turbuhaler. Int. J. Pharm. 97:47-53.
29. Borgstrom, L., E. Bondesson, F. Moren, E. Trofast, and S. P. Newman. 1994. Lung deposition of budesonide inhaled via turbuhaler: a comparison with terbutaline sulphate in normal subjects. Eur. Respir. J. 7:69-73.
30. Beckman, O., E. Bondesson, L. Asking, A. Kallen, and L. Borgstrom. 1995. Intra- and inter-individual variation in pulmonary deposition via turbuhaler and pMDI. In Drug Delivery to the Lungs VI. London. 138-141.
31. Leach, C. 1996. Enhanced drug delivery through reformulating MD1s with HFA propellants: drug deposition and its effect on preclinical and clinical programs. In R. N. Dalby, P. R. Byron, and S. J. Farr, editors. Respiratory Drug Delivery V Proceedings. Interpharm Press, Buffalo Grove, IL. 133-144.